The announcement by Enveric Biosciences regarding its novel compounds suggests a strategic move towards leveraging its intellectual property for financial gain without diluting shareholder equity. This approach not only preserves the value for current shareholders but also potentially opens up new revenue streams through licensing. Given the emphasis on non-dilutive funding, this news is likely to be viewed positively by investors, as it indicates a path towards financial growth and stability without the risk of diluting existing shares. The confidence in this analysis is based on the direct mention of these strategic initiatives and their implications for the company's financial health.